Global Health Investment Corporation

What Global Health Investment Corporation does

Global Health Investment Corporation (GHIC) is a nonprofit investment corporation founded in 2012 and headquartered in New York that mobilizes public, philanthropic, and private capital to invest in life sciences and healthcare technology companies developing products for global public health and health security. Its portfolio spans vaccines, therapeutics, diagnostics, medical devices, biosensors, microarray patches, biosynthetic pharmaceutical ingredients, and RNA medicines, with particular emphasis on infectious diseases (HIV/AIDS, malaria, tuberculosis, cholera, influenza, sepsis) and pandemic preparedness. GHIC does not develop proprietary technology products; instead, it deploys venture-capital methodologies through a set of specialized investment vehicles and partnerships.

The firm's core operating assets are four funds and platforms: the Global Health Investment Fund (GHIF), a $108M social-impact fund that invested in 12 companies whose products have reached over 500 million people; the Global Health Security Fund (GHSF), launched May 2026 with $353M in commitments from BARDA, CEPI, Flu Lab, Eli Lilly, Meiji Seika Pharma, MITRE, and WARF; the Catalytic Health Investment Platform (CHIP), a 20-year partnership with KfW Development Bank on behalf of Germany's BMZ with up to €60M in initial funding; and the Frontier Fund, a $20M non-dilutive research and fellowship program running 2024–2028. Underpinning these is a 10-year, up-to-$500M partnership with BARDA Ventures (signed 2021) supplemented by a $100M Project NextGen award (2023). GHIC also makes LP commitments into third-party funds targeting health equity (Cross-Border Impact Ventures, AfricInvest Transform Health Fund, Verge HealthTech Fund II).

GHIC's revenue mechanics come from two streams: (1) management fees and partnership revenue from the funds and platforms it operates on behalf of BARDA, KfW, CEPI, Gates Foundation, and corporate LPs; and (2) returns on its venture investments, which as a nonprofit are recycled into mission-related deployment rather than distributed. The organization is governed by a board of directors and led by Chairman and CEO Labeeb M. Abboud, Chief Investment Officer and Senior Managing Director Vidya Vasu-Devan, and Managing Director Charlie Petty, with a lean team of 1–10 staff supplemented by partners (Damien Soghoian), principals (Joseph Lee), and a Head of Science (Devin Sok) leading the Frontier Fund.

Name

Global Health Investment Corporation

Legal name

Global Health Investment Corporation

Website

https://ghicfunds.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Global Health Investment Corporation (GHIC) is a New York-based nonprofit founded in 2012 that operates venture funds and partnerships to invest in life sciences and healthcare technology companies developing vaccines, therapeutics, diagnostics, and devices for global health security.

Ownership category

akta.pro rank

Product category

Impact Investment Management

NAICS

Other Financial Vehicles (52599), Grantmaking Foundations (813211)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industries

Global Health Financing Mechanisms (HLAJAKAC), Health Research Funding Agencies (Public/Quasi-Public) (HLAJALAB)

Keywords

• Global health venture capital
• Impact investment management
• Health security funding
• Biotech venture financing
• Pandemic preparedness investment

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment Returns and Financial Returns: GHIC generates returns on its venture investments in portfolio companies developing global health technologies. As a nonprofit organization, returns are reinvested to generate additional health security impact. The firm also mobilizes matching capital from public, philanthropic, and private sectors alongside its own investments.
2. Management Fees and Partnership Revenue: GHIC operates investment funds (GHIF, GHSF, CHIP, Frontier Fund) and charges management fees or similar arrangements with partners including BARDA, KfW, and other investors. BARDA provided a minimum of $50M over five years with potential for up to $500M over 10 years for the BARDA Ventures partnership.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

GHIC is a nonprofit investment corporation that deploys venture capital and non-dilutive funding into life-sciences and healthcare-technology companies developing vaccines, therapeutics, diagnostics, medical devices, and biomanufacturing technologies for global health and health security. It operates specialized funds (GHIF, GHSF, CHIP, Frontier Fund) and accepts outside capital from governments, foundations, and corporates to co-invest in mission-aligned portfolio companies alongside its own commitments.

Product overview

Global Health Investment Corporation (GHIC) is a nonprofit investment organization that operates multiple specialized investment vehicles rather than a unified product platform. Its core offerings include the Global Health Investment Fund (GHIF), a $108 million social impact fund targeting infectious diseases in low- and middle-income countries; the Global Health Security Fund (GHSF), a BARDA-partnered venture fund for pandemic preparedness technologies; the Catalytic Health Investment Platform (CHIP), a twenty-year €60 million partnership with the German government; and the Frontier Fund, a $20 million non-dilutive funding program for early-stage global health security research.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Health Investment Fund (GHIF) A $108 million social impact fund that invested in twelve companies developing clinical diagnostics, devices, vaccines, and therapeutics targeting infectious diseases disproportionately burdening low- and middle-income countries (HIV/AIDS, malaria, tuberculosis, cholera). GHIF portfolio companies have commercialized more than a dozen products reaching over 500 million people.
• Global Health Security Fund (GHSF) A venture capital fund sponsored by GHIC in partnership with BARDA that supports development and commercialization of technologies responding to or preventing public health emergencies (pandemics, other global health security threats). Launched with $353M in commitments from BARDA, CEPI, Flu Lab, Eli Lilly, Meiji Seika Pharma, MITRE, WARF, and CHIP.
• Catalytic Health Investment Platform (CHIP) A twenty-year partnership between GHIC and the Government of Germany (through BMZ and KfW Development Bank) to accelerate development of public health technologies and products that improve global health, with initial funding commitment of up to €60 million. CHIP also deploys capital into funds-of-funds investments such as AfricInvest's Transform Health Fund, Verge HealthTech Fund II, and CBIV's Women's and Children's Health Technology Fund.
• Frontier Fund A $20 million non-dilutive funding program launched in October 2024 to catalyze and support innovations in global health security through early-stage translational research, high-risk/high-impact projects, and fellowships from 2024 to 2028. Funded by BARDA's Division of Research, Innovation, and Ventures (DRIVe).

Quantifiable outcome

• Over 500 million people reached by portfolio companies' products
• +3 more outcomes

Named customers12 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• MITRE CorporationcoreStrategic or Co-development PartnerGHIC launched a strategic collaboration with MITRE to foster shared goals of strengthening global health security and advancing medical countermeasure technologies. MITRE provides analysis, evaluation, and funding to enable GHIC to expand mission-aligned investment activities.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development PartnerCEPI and GHIC signed an MoU to enhance cooperation in vaccine research, development, manufacturing, and stockpiling. Partners share information and expertise relevant to medical countermeasures and pursue opportunities for practical cooperation including joint funding of vaccine development platforms and technologies.
• BlueMarkminorImplementation/ SI/ Consulting PartnerGHIC's Catalytic Health Investment Platform partnered with BlueMark to strengthen impact practices and performance of fund managers investing in healthcare innovation for underserved populations. The partnership deploys BlueMark's fund verification process and portfolio analytics.
• DRIVe (Transforming Health Security)coreStrategic or Co-development PartnerDRIVe (Division of Research, Innovation, and Ventures) within BARDA works closely with GHIC to prioritize efforts within the partnership that have the highest potential impact on BARDA's mission.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Adjuvant Capital: Adjuvant Capital is a venture firm investing in life sciences technologies addressing infectious disease, women's health, and climate-adjacent public health priorities in low- and middle-income countries. It is the closest direct peer to GHIC, operating a similar public-private-capital-backed VC model targeting global health product development with BARDA and foundation partnerships.
• Acumen: Acumen is a nonprofit impact investment organization that deploys patient capital into early-stage companies addressing poverty across health, agriculture, and energy in emerging markets. It shares GHIC's nonprofit structure, mission-driven mandate, and use of concessional public/philanthropic capital to back healthcare innovation in LMICs.
• MedAccess: MedAccess is a UK-based social enterprise that uses volume guarantees and innovative finance to accelerate access to medical products in LMICs. It is comparable to GHIC in deploying blended-finance mechanisms (often alongside GHIC in deals) to expand access to vaccines, therapeutics, and diagnostics for global health priorities.
• Bridges Fund Management: Bridges Fund Management is a UK-based impact investment firm managing multiple strategies across private equity, venture, and fixed income for social and environmental outcomes. Comparable to GHIC in operating a multi-vehicle impact platform with institutional LPs and dedicated health/environmental outcomes strategies.
• LeapFrog Investments: LeapFrog Investments is a profit-with-purpose growth equity firm that invests in healthcare, financial services, and consumer businesses serving emerging-market consumers. Comparable to GHIC in scaling private capital for global health and financial inclusion in Africa and Asia, though operating as a commercial fund manager.

Others

• Unitaid: Unitaid is a global health financing mechanism hosted by WHO that invests in scaling access to innovative health products for HIV, TB, malaria, and emerging threats. It is adjacent and ecosystem-related to GHIC, operating in the same global-health capital stack but focused on mature product adoption rather than early-stage venture equity.

Broad incumbents

• CEPI (Coalition for Epidemic Preparedness Innovations): CEPI is a global partnership that finances and coordinates the development of vaccines against epidemic threats. It is a major GHIC partner (LP in GHSF, MoU cooperator) and a broader incumbent in the global health security ecosystem, though CEPI primarily uses grants and push funding rather than venture equity.
• Bill & Melinda Gates Foundation (Strategic Investment Fund): The Gates Foundation's Strategic Investment Fund deploys program-related investments into life sciences companies addressing global health and development. It is a co-founding partner in GHIF and broader incumbent in global health capital, operating at vastly greater scale than GHIC across direct investments and grantmaking.
• Wellcome Trust (Investments division): Wellcome Trust is a major charitable foundation supporting health research through grantmaking and impact investment. It operates a sizable investment portfolio backing life sciences ventures and is a broader incumbent in the global-health financing ecosystem that overlaps with GHIC's mission and LP base.
• Khosla Ventures: Khosla Ventures is a large US venture firm that invests broadly in technology and life sciences, including health and sustainability impact themes. It is a broader incumbent that occasionally co-invests with GHIC (e.g., Future Ventures co-led Centivax rounds with GHIC participants), but is not mission-locked to global health security.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Health Investment Corporation